F. Hoffmann-La Roche AG;Chugai Seiyaku Kabushiki Kaisha
发明人:
Toshihiko OHTOMO,Takayoshi TANAKA,Mikiko NAKAMURA
申请号：
US16649039
公开号：
US20200216542A1
申请日:
2018.09.19
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Provided are dosage regimens for combination therapy using PD-1 axis binding antagonists and GPC3 targeting agent. For example, the dosage regimens comprise (i) a loading period within which the GPC3 targeting agent is administered, followed by (ii) a maintenance period within which the PD-1 axis binding antagonist and the GPC3 targeting agent are administered.
